Our Discoveries

Inactivating the WRN protein could kill colorectal and other cancer cells

Rapid inactivation of the Werner Syndrome helicase (WRN), a protein upon which cancer cells that exhibit microsatellite instability often rely for survival, could be effective in killing colorectal and other cancer cells and potentially guide the development of inhibitor drugs.

FDA grants orphan drug designation to indotecan for the treatment of glioma

The U.S. Food and Drug Administration (FDA) granted orphan drug status to LMP400 (indotecan) for use in patients with malignant glioma, a cancer of the brain that begins in glial cells (cells that surround and support nerve cells).

Population-specific tumor mutation patterns may reflect breast cancer health disparities

African American, European American and Kenyan patients with breast cancer have different patterns of tumor mutations.

New insights show faulty immune cells are trained to become healthy

Researchers traditionally believed faulty T cells that have the potential to attack someone’s own tissues were eliminated before the cells leave the thymus. Now, research in mice shows that these autoreactive cells are evicted from the thymus and can mature into healthy cancer-fighting cells in the body’s peripheral tissues. This basic science discovery holds important implications for our understanding of autoimmune diseases and cancer.

New technology assists T-cell therapy in eradicating solid tumors in mice

A new technology targeted at T-cell therapy may help immunotherapy overcome the treatment-hindering environment inside solid tumors.

Gene therapy proves successful in children with Wiskott-Aldrich syndrome

Wiskott-Aldrich syndrome (WAS) is a rare genetic disorder where males lack a gene critical for healthy blood and immune cell functioning. In a recent clinical trial, gene therapy for WAS was found to improve patients’ symptoms — an effect that was sustained for many years afterward.

New CAR T-cell therapy eliminates rhabdomyosarcoma in mice

After seeing excellent results of a CAR T-cell therapy against rhabdomyosarcoma in mice, a team of CCR researchers is preparing to test the immunotherapy in humans.

New findings highlight shared features of human and canine osteosarcoma

Molecular signatures of canine osteosarcoma prognosis could also predict clinical outcomes for human osteosarcomas.

Shining a light on an elusive cancer metabolite

Researchers have long sought a means for subcellular imaging of acetyl-CoA, a metabolite suspected to play a critical role in turning genes on and off. In an important advance, CCR researchers have invented a glowing biosensor to detect the elusive metabolite, paving the way for future studies.

Seldom-studied immune cells in the liver may be helpful in treating cancer

CCR researchers have discovered that certain immune cells in the liver, called MAITs, often surround liver tumors but fail to infiltrate them. An analysis suggests that treatment with immune checkpoint inhibitors could potentially trigger these immune cells to help them infiltrate and attack the tumors.

Breadcrumb